Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy

Stefano Indraccolo, S. Minuzzo, E. Gola, W. Habeler, F. Carrozzino, D. Noonan, A. Albini, L. Santi, A. Amadori, L. Chieco-Bianchi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated and characterized in vitro. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 293T cells, followed by Western blotting (WB) or radioimmunoprecipitation analysis of both cell lysates and supernatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inhibitors.

Original languageEnglish
Pages (from-to)251-256
Number of pages6
JournalInternational Journal of Biological Markers
Volume14
Issue number4
Publication statusPublished - Oct 1999

Fingerprint

Angiostatins
Endostatins
Tissue Inhibitor of Metalloproteinase-2
Gene therapy
Angiogenesis Inhibitors
Neoplasm Genes
Genetic Therapy
Plasmids
Radioimmunoprecipitation Assay
Oncology
HEK293 Cells
Transcription
Recombinant Proteins
Nucleic Acids
Transfection
Tumors
Neoplasms
Animals
Animal Models
Complementary DNA

Keywords

  • Angiostatin
  • Endostatin
  • Gene therapy
  • Retroviral vectors
  • TIMP-2

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. / Indraccolo, Stefano; Minuzzo, S.; Gola, E.; Habeler, W.; Carrozzino, F.; Noonan, D.; Albini, A.; Santi, L.; Amadori, A.; Chieco-Bianchi, L.

In: International Journal of Biological Markers, Vol. 14, No. 4, 10.1999, p. 251-256.

Research output: Contribution to journalArticle

Indraccolo, Stefano ; Minuzzo, S. ; Gola, E. ; Habeler, W. ; Carrozzino, F. ; Noonan, D. ; Albini, A. ; Santi, L. ; Amadori, A. ; Chieco-Bianchi, L. / Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. In: International Journal of Biological Markers. 1999 ; Vol. 14, No. 4. pp. 251-256.
@article{6efbe83eff104b32a256fda33058838d,
title = "Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy",
abstract = "Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated and characterized in vitro. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 293T cells, followed by Western blotting (WB) or radioimmunoprecipitation analysis of both cell lysates and supernatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inhibitors.",
keywords = "Angiostatin, Endostatin, Gene therapy, Retroviral vectors, TIMP-2",
author = "Stefano Indraccolo and S. Minuzzo and E. Gola and W. Habeler and F. Carrozzino and D. Noonan and A. Albini and L. Santi and A. Amadori and L. Chieco-Bianchi",
year = "1999",
month = "10",
language = "English",
volume = "14",
pages = "251--256",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy

AU - Indraccolo, Stefano

AU - Minuzzo, S.

AU - Gola, E.

AU - Habeler, W.

AU - Carrozzino, F.

AU - Noonan, D.

AU - Albini, A.

AU - Santi, L.

AU - Amadori, A.

AU - Chieco-Bianchi, L.

PY - 1999/10

Y1 - 1999/10

N2 - Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated and characterized in vitro. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 293T cells, followed by Western blotting (WB) or radioimmunoprecipitation analysis of both cell lysates and supernatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inhibitors.

AB - Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated and characterized in vitro. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 293T cells, followed by Western blotting (WB) or radioimmunoprecipitation analysis of both cell lysates and supernatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inhibitors.

KW - Angiostatin

KW - Endostatin

KW - Gene therapy

KW - Retroviral vectors

KW - TIMP-2

UR - http://www.scopus.com/inward/record.url?scp=0033374458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033374458&partnerID=8YFLogxK

M3 - Article

C2 - 10669955

AN - SCOPUS:0033374458

VL - 14

SP - 251

EP - 256

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -